
Jun Cheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/277384/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). Journal of Clinical and Translational Hepatology, 2017, 5, 297-318.	1.4	181
2	Rutin ameliorates obesity through brown fat activation. FASEB Journal, 2017, 31, 333-345.	0.5	151
3	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut, 2016, 65, 313-320.	12.1	112
4	Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virology Journal, 2015, 12, 109.	3.4	36
5	miR-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis. Molecular Therapy - Nucleic Acids, 2018, 10, 91-102.	5.1	31
6	Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World Journal of Hepatology, 2016, 8, 637.	2.0	22
7	The peptide encoded by a novel putative IncRNA HBVPTPAP inducing the apoptosis of hepatocellular carcinoma cells by modulating JAK/STAT signaling pathways. Virus Research, 2020, 287, 198104.	2.2	21
8	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatology International, 2019, 13, 260-269.	4.2	18
9	A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatology International, 2012, 6, 441-448.	4.2	17
10	Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma. Molecular Medicine Reports, 2015, 11, 4053-4062.	2.4	17
11	Role of ILâ€6â€mediated expression of NS5ATP9 in autophagy of liver cancer cells. Journal of Cellular Physiology, 2018, 233, 9312-9319.	4.1	17
12	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opinion on Biological Therapy, 2018, 18, 61-69.	3.1	17
13	HCBP6 Modulates Triglyceride Homeostasis in Hepatocytes Via the SREBP1c/FASN Pathway. Journal of Cellular Biochemistry, 2015, 116, 2375-2384.	2.6	16
14	Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography. PLoS ONE, 2017, 12, e0170073.	2.5	16
15	Regulation of HepG2 cell apoptosis by hepatitis C virus (HCV) core protein via the sirt1–p53–bax pathway. Virus Genes, 2015, 51, 338-346.	1.6	15
16	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. Journal of Clinical Virology, 2014, 61, 509-516.	3.1	14
17	HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice. Biomedicine and Pharmacotherapy, 2020, 129, 110347.	5.6	13
18	Hepatitis C virus core protein induces hepatic steatosis via Sirt1â€dependent pathway. Liver International, 2018, 38, 803-812.	3.9	12

JUN CHENG

#	Article	lF	CITATIONS
19	Prevalence of NS5B resistance-associated variants in treatment-naÃ⁻ve Asian patients with chronic hepatitis C. Archives of Virology, 2018, 163, 467-473.	2.1	12
20	NS5ATP9 Promotes Beclin 1-Dependent Starvation-Induced Autophagy of Hepatoblastoma Cells. Journal of Cellular Biochemistry, 2015, 116, 1574-1582.	2.6	10
21	Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing. Microbial Drug Resistance, 2017, 23, 253-260.	2.0	10
22	Prediction of oesophageal varices in patients with primary biliary cirrhosis by non-invasive markers. Archives of Medical Science, 2017, 2, 370-376.	0.9	10
23	Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection. Chinese Medical Journal, 2018, 131, 43-49.	2.3	10
24	Oral delivery of a Lactococcus lactis expressing extracellular TGFβR2 alleviates hepatic fibrosis. Applied Microbiology and Biotechnology, 2021, 105, 6007-6018.	3.6	10
25	Renal abscess caused by Brucella. International Journal of Infectious Diseases, 2014, 28, 26-28.	3.3	9
26	Simeprevir plus peginterferon/ribavirin for HCV genotype 1â€infected treatmentâ€naÃ⁻ve patients in China and South Korea. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 912-920.	2.8	8
27	Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-10.	1.9	8
28	Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placeboâ€controlled phase 2 trial. Journal of Digestive Diseases, 2018, 19, 144-154.	1.5	7
29	S6K1 inhibits HBV replication through inhibiting AMPK-ULK1 pathway and disrupting acetylation modification of H3K27. Life Sciences, 2021, 265, 118848.	4.3	7
30	HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virology Journal, 2016, 13, 180.	3.4	6
31	NS5ATP6 modulates intracellular triglyceride content through FGF21 and independently of SIRT1 and SREBP1. Biochemical and Biophysical Research Communications, 2016, 475, 133-139.	2.1	6
32	Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterology, 2020, 20, 391.	2.0	6
33	Cell culture-adaptive mutations in hepatitis C virus promote viral production by enhancing viral replication and release. World Journal of Gastroenterology, 2018, 24, 1299-1311.	3.3	5
34	HCBP6 upregulates human SREBP1c expression by binding to C/EBPβ-binding site in the SREBP1c promoter. BMB Reports, 2018, 51, 33-38.	2.4	5
35	Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Scientific Reports, 2017, 7, 10289.	3.3	4
36	Nomogram to Predict the Survival of Chinese Patients with Alcohol-Related Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-8.	1.9	4

JUN CHENG

#	Article	IF	CITATIONS
37	Screening of hepatocyte proteins binding with C-terminally truncated surface antigen middle protein of hepatitis B virus (MHBst167) by a yeast two-hybrid system. Molecular Medicine Reports, 2014, 10, 1259-1263.	2.4	3
38	NS5ATP13 Promotes Liver Fibrogenesis Via Activation of Hepatic Stellate Cells. Journal of Cellular Biochemistry, 2017, 118, 2463-2473.	2.6	3
39	Transactivation of proto-oncogene c-Myc by hepatitis B virus transactivator MHBst167. Oncology Letters, 2014, 8, 803-808.	1.8	2
40	De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 24.	3.8	2
41	XTP8 promotes hepatocellular carcinoma growth by forming a positive feedback loop with FOXM1 oncogene. Biochemical and Biophysical Research Communications, 2019, 515, 455-461.	2.1	2
42	Hepatitisïį¼C virus nonstructuralïį½5A protein inhibits the starvationâ€ʻinduced apoptosis of hepatoblastoma cells by increasing Beclinïį½1 expression. Oncology Reports, 2019, 41, 3051-3059.	2.6	2
43	Serum IL‑21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues. Experimental and Therapeutic Medicine, 2021, 21, 216.	1.8	2
44	Short hairpin RNAs with a 2- or 3-base mismatch inhibit HBV expression and replication in HepG2 cells. Hepatology International, 2013, 7, 127-133.	4.2	1
45	Screening of hepatocyte proteins binding with the middle surface protein of the hepatitis B virus by the yeast two-hybrid system. Molecular Medicine Reports, 2014, 9, 2342-2346.	2.4	1
46	Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World Journal of Clinical Cases, 2021, 9, 4690-4699.	0.8	0
47	Chinese Consensus on Antiviral Treatment of Chronic Hepatits B Patients with Nucleos(t)ide Analogues. Infection International, 2013, 2, 90-96.	0.1	Ο